Hospital Infection Therapeutics Market Applications by 2030

Comments · 83 Views

Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030

Hospital infection therapeutics refers to pharmaceutical drugs used to treat hospital nosocomial infections. These infections can occur in hospitals, nursing homes, rehabilitation centers, and other clinical settings and are typically treated with antiviral, antibacterial, and antifungal medications. Vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides, and tigecycline are antibacterial therapeutics inhibiting cell wall synthesis and protein synthesis. Caspofungin and Amphotericin B are antifungal therapeutics that help to prevent hospital-acquired pneumonia, urinary tract infections (UTIs), bloodstream infections, and surgical site infections.


According to the World Health Organization (WHO), for every 100 hospitalized patients, 10 in developed countries and 7 in developing countries acquire at least one healthcare-associated infection. Urinary tract infections are expected to have a significant share of the indications segment and grow significantly. The increasing number of patients with urinary tract infections and ongoing research and development on urinary tract infection treatment are attributed to the growth. Furthermore, the growing elderly population and the prevalence of hospital-acquired infections will drive overall market growth during the forecast period.


Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.


North America dominates the hospital infection therapeutics market due to the increasing occurrences of chronic disorders, the rising prevalence of the geriatric population, and the growing number of research and development activities.


Request a Sample Copy @


Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the development of healthcare infrastructure and surging levels of investment for the growth of the healthcare system.


Some of the major players operating in the hospital infection therapeutics market are:


Merck Co., Inc. (U.S.)
Pfizer Inc. (U.S.)
GSK plc. (U.K.)
AstraZeneca (U.K.)
Johnson Johnson Services, Inc. (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG (Germany)
AbbVie Inc. (U.S.)
Sanofi (France)
Gilead Sciences, Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Basilea Pharmaceutica Ltd. (Switzerland)
Spero Therapeutics (U.S.)
BioSpace (Canada)
POLYPID (Israel)
Novartis AG (Switzerland)
Bellerophon Therapeutics (U.S.)
Achilles Therapeutics plc. (U.K.)


Related Reports:


Infection Control Market


Medical Instruments Disinfections Market


Yeast Infection Market


About Data Bridge Market Research, Private Ltd


Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.


Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”



Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475